Commentary
Volume 15:01, 2025

Bioceramics Development and Applications

ISSN: 2090-5025 Open Access

Bioceramics in Cancer Treatment: Nanostructures for Targeted Drug Delivery

Phoebe Langford*

Department of Biomedical Engineering, RMIT University, 124 La Trobe St., Melbourne, VIC 3000, Australia

Introduction

Bioceramics have emerged as a promising class of materials in oncology, particularly in the realm of targeted drug delivery, owing to their unique physicochemical properties, high biocompatibility and structural versatility. In cancer therapy, the ability to deliver chemotherapeutic agents precisely to tumor sites while minimizing systemic toxicity is a central challenge and nanostructured bioceramics offer a strategic solution. These materials, often derived from hydroxyapatite, silica, or calcium phosphate compounds, can be engineered at the nanoscale to encapsulate and release drugs in response to specific physiological triggers, such as pH or temperature changes in the tumor microenvironment. As a result, nanostructured bioceramics represent a frontier in precision medicine, facilitating more effective and safer treatment regimens for various malignancies [1].

Description

Nanostructured bioceramics serve as efficient drug carriers due to their tunable pore size, high surface area and ability to be functionalized with targeting ligands or therapeutic agents. Mesoporous silica nanoparticles (MSNs), for example, have shown remarkable potential in delivering anticancer drugs like doxorubicin, paclitaxel and cisplatin directly to tumor cells while bypassing healthy tissues. The surface of these nanocarriers can be modified with tumor-targeting peptides, antibodies, or aptamers, enhancing their selectivity and uptake by cancerous cells. Moreover, the degradation profile of these materials can be customized to release their payloads in response to the acidic pH characteristic of tumor environments, thereby ensuring that the drugs are activated only where needed.

Another advantage of bioceramic nanostructures is their multifunctionality, which enables simultaneous imaging and therapy, a concept known as theranostics. Certain bioceramic particles can be doped with contrast agents or radioactive isotopes, allowing clinicians to track drug distribution via imaging techniques like MRI, PET, or CT scans. This integration of diagnosis and treatment within a single platform not only improves monitoring but also allows for real-time adjustments in therapeutic strategy. Additionally, bioceramic materials can be loaded with more than one therapeutic agent, enabling synergistic treatment approaches such as combined chemotherapy and immunotherapy, which may be particularly effective against resistant or aggressive tumor types.

Despite their promise, bioceramic nanocarriers face several translational hurdles. Challenges include controlling particle size distribution for consistent pharmacokinetics, ensuring long-term biosafety and scaling up production while maintaining quality and reproducibility. Immune system clearance, potential toxicity due to degradation byproducts and regulatory complexities are also significant concerns that must be addressed before widespread clinical adoption. Nevertheless, ongoing research continues to refine these systems through advancements in surface engineering, hybrid material synthesis and in vivo modeling, gradually overcoming the barriers to their implementation in standard cancer care [2].

Conclusion

In summary, nanostructured bioceramics represent a powerful and innovative tool in cancer treatment, offering highly specific, minimally invasive and effective drug delivery mechanisms that align with the goals of personalized medicine. Their ability to target tumor tissues, respond to environmental cues and integrate diagnostic functionalities sets them apart from conventional drug carriers. While challenges remain in their clinical translation, the progress in material science, nanotechnology and biomedical engineering suggests a strong future for bioceramic-based platforms in oncology. Continued interdisciplinary research and collaboration will be critical in optimizing these systems for human use, ultimately transforming how cancer is treated through smarter, safer and more efficient therapeutic strategies.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Liu, Shuai, Wei Yang, Yunlei Li and Changqing Sun. "Fetal bovine serum, an important factor affecting the reproducibility of cell experiments." *Sci Rep* 13 (2023): 1942.

2. Piletz, John E., Jennifer Drivon, John Eisenga and Will Buck, et al. "Human cells grown with or without substitutes for fetal bovine serum." *Cell Med* 10 (2018): 2155179018755140.

***Address for Correspondence:** Phoebe Langford, Department of Biomedical Engineering, RMIT University, 124 La Trobe St., Melbourne, VIC 3000, Australia; E-mail: phoebe@langford.au*

Received: 01 March, 2025, Manuscript No. bda-25-169220; **Editor Assigned:** 03 March 2025, Pre-QC No. P-169220; **Reviewed:** 17 March, 2025, QC No. Q-169220; **Revised:** 22 March, 2025, Manuscript No. R-169220; **Published:** 31 March, 2025, DOI: 10.37421/2090-5025.2025.15.287

How to cite this article: Langford, Phoebe. "Bioceramics in Cancer Treatment: Nanostructures for Targeted Drug Delivery." *Bioceram Dev Appl* 15 (2025): 287.